Klaria receives 6.4 MSEK milestone payment from EU’s Horizon 2020 program to take Sumatriptan Alginate Film to market
Today, Klaria Pharma Holding AB (publ) announces that the company has received a milestone payment of 6.4 MSEK from the EU’s Horizon 2020 program. The payment is made as the development of Sumatriptan Alginate film (KL-00119) continues to proceed successfully according to plan. Large-scale production of the product is on-going, and all preparations for the upcoming bioequivalence study are completed. This pivotal clinical study required for submission of approval is planned to start in the first half of 2020 with completion in 2020.The milestone payment of 6.4 MSEK is expected to cover